The narrative review by Choudhary et al1 thoughtfully revisits a persistent challenge in urologic oncology: how to reconcile the functional benefits of urinary diversion with its well-recognized metabolic and secretory morbidities. Although ileal conduits and orthotopic neobladders remain durable and oncologically sound options, long-term complications, including bowel complications, metabolic acidosis, vitamin deficiencies, mucus production, urinary tract infections, stone formation, and renal deterioration, underscore the risks inherent in repurposing bowel for urinary storage. The authors appropriately highlight tissue engineering and vascularized composite bladder allograft transplantation as emerging strategies to mitigate gut-related complications. The early promise of autologous tissue-engineered constructs described by Atala et al2 was tempered by subsequent translational challenges, particularly related to scaffold integration, vascularization, and functional innervation. The review's discussion of neovascularization and neural regeneration are central barrier to clinically meaningful bladder replacement. Bladder transplantation represents a conceptual paradigm shift. Recent first-in-human efforts and ongoing trials suggest technical feasibility, but long-term graft durability, immunologic risk, and patient selection criteria remain undefined.3 For benign indications, the risk-benefit calculus of lifelong immunosuppression is especially complex. Accordingly, innovation in this space must proceed in parallel with rigorous ethical and functional outcome evaluation. Importantly, the review reminds us that the “ideal” diversion must be measured not only by surgical feasibility but also by metabolic neutrality, compliance, continence, durability, and patient-reported quality of life. As robotic surgery, regenerative medicine, and transplantation science converge, multidisciplinary collaboration is critical. While gut-based diversion remains the current standard, the future of bladder substitution is entering an exciting era marked by rapid innovation and translational advances.
Building similarity graph...
Analyzing shared references across papers
Loading...
Divya Ajay
JU Open Plus
Memorial Sloan Kettering Cancer Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Divya Ajay (Wed,) studied this question.
synapsesocial.com/papers/69d895a86c1944d70ce06c20 — DOI: https://doi.org/10.1097/ju9.0000000000000443